GI Dynamics advances weight loss advice

GI Dynamics has a fresh set of positive clinical results from three studies of its EndoBarrier Gastrointestinal Liner, a device used to treat type 2 diabetes, weight loss and other metabolic factors. And results from one study showed that EndoBarrier had an impact on hormonal activity in patients with the device.

GI describes the EndoBarrier is a non-surgical, removable, physical barrier (pictured here) that enables food to bypass portions of the intestine. It has a similar effect as gastric bypass with fewer associated risks. The device can "reset" the body's metabolic functions to a more normalized state.

In a 24-week trial with 17 people, researchers found that the device improved insulin sensitivity, promoted weight loss and helped patients reduce their use of anti-diabetic medications. "These data reveal that EndoBarrier treatment affects key hormones involved in insulin sensitivity and satiety, which is likely the cause for the rapid improvement seen in type 2 diabetes," said study leader Professor Jan Willem Greve. "This supports the belief that the EndoBarrier works by affecting hormone activation and that the device is a promising tool for the treatment of type 2 diabetes in obese individuals."

The company believes the trial results support EndoBarrier as primary therapy for the treatment of type 2 diabetes and obesity in patients with a body mass index (BMI) greater than 30 who haven't succeeded with lifestyle changes and drugs alone. 

- take a look at the release

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.